GNRH2 Polymorphism in Men With Prostate Cancer Treated With Androgen Deprivation Therapy.

ABSTRACT:

Background/aim

Gonadotropin-releasing hormone 2 (GNRH2) is a poorly-studied peptide hormone that is widely distributed in the central nervous system and expressed in peripheral tissues of mammals. The non-synonymous rs6051545 variant in GNRH2 (A16V) has been linked to higher serum testosterone concentrations. This study investigated whether the A16V variant is associated with altered androgen-deprivation therapy (ADT) progression-free survival (PFS) and overall survival (OS).

Patients and methods

We examined the expression of GNRH2 in prostate tissue microarrays comprising normal tissue, prostatic hyperplasia, and prostate cancer using immunofluorescence. We also evaluated the GNRH2 genotype in 131 patients with prostate cancer who received ADT and compared PFS and OS betwee

SUBMITTER: Sissung TM 

PROVIDER: S-EPMC10760530 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature